In a filing, Tourmaline Bio Inc revealed its Director MCDADE MARK acquired Company’s shares for reported $3.25 million on Jan 29 ’24. In the deal valued at $32.50 per share,100,000 shares were bought. As a result of this transaction, MCDADE MARK now holds 448,431 shares worth roughly $6.93 million.
Then, Kulkarni Sandeep Chidambar bought 4,000 shares, generating $67,960 in total proceeds. Upon buying the shares at $16.99, the CEO now owns 729,735 shares.
Before that, Thiara Parvinder bought 1,000 shares. Tourmaline Bio Inc shares valued at $17,310 were divested by the Director at a price of $17.31 per share. As a result of the transaction, Thiara Parvinder now holds 83,782 shares, worth roughly $1.29 million.
Jefferies initiated its Tourmaline Bio Inc [TRML] rating to a Buy in a research note published on December 15, 2023; the price target was $41. Truist began covering TRML with “Buy” recommendation on November 17, 2023. Guggenheim started covering the stock on October 31, 2023. It rated TRML as “a Buy”.
Price Performance Review of TRML
On Friday, Tourmaline Bio Inc [NASDAQ:TRML] saw its stock fall -1.34% to $15.45. Over the last five days, the stock has lost -23.33%. Tourmaline Bio Inc shares have fallen nearly -40.99% since the year began. Nevertheless, the stocks have fallen -29.77% over the past one year. While a 52-week high of $48.31 was reached on 03/13/24, a 52-week low of $9.18 was recorded on 04/19/24. SMA at 50 days reached $32.06, while 200 days put it at $27.48. A total of 0.74 million shares were traded, compared to the trading of 0.55 million shares in the previous session.
Levels Of Support And Resistance For TRML Stock
The 24-hour chart illustrates a support level at 15.05, which if violated will result in even more drops to 14.65. On the upside, there is a resistance level at 15.93. A further resistance level may holdings at 16.41. The Relative Strength Index (RSI) on the 14-day chart is 22.89, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.27%. Stochastics %K at 3.12% indicates the stock is a buying.
The most recent change occurred on October 25, 2023 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
